Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00121667 · ClinicalTrials.gov registry record · Phase 3

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
1,462
Enrollment target
20
Study locations

NCT00121667: Completed Phase 3 study of Diabetes Mellitus, Type 2, sponsored by AstraZeneca.

NCT00121667 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by AstraZeneca. The registered enrollment target is 1,462 participants, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00121667, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
1,462 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone

Primary Outcome

Mean change from baseline is adjusted for baseline value.

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG Pioglitazone
  • DRUG Saxagliptin + Metformin
  • DRUG Placebo + Metformin

Study Locations (20)

California

  • Local Institution - Encino
  • Local Institution - Fountain Valley
  • Local Institution - Fresno
  • Local Institution - Los Angeles
  • Local Institution - Mission Viejo
  • Local Institution - Northridge
  • Local Institution - Orange
  • Local Institution - Roseville
  • Local Institution - Sacramento
  • Local Institution - Spring Valley
  • Local Institution - Tustin

Alabama

  • Local Institution - Anniston
  • Local Institution - Birmingham
  • Local Institution - Calera
  • Local Institution - Haleyville

Arkansas

  • Local Institution - Jonesboro
  • Local Institution - Little Rock
  • Local Institution - Sherwood

Arizona

  • Local Institution - Mesa
  • Local Institution - Phoenix

Trial Details

FieldValue
Enrollment Target 1,462 participants
Start Date 2005-08
Est. Completion 2010-02
Phase Phase 3
AstraZeneca

1,285 total trials

What the finished NCT00121667 record still lists

NCT00121667 is an interventional study that assigns participants to a tested intervention. Its 1,462 participants enrollment target places it among the larger protocols in the corpus, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Pioglitazone is the first listed.

NCT00121667 names 20 study sites across 4 states, led by California, Alabama, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00121667 about?

NCT00121667 is a clinical study titled "Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone". The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone

What is the current status of trial NCT00121667?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,462 participants. The study started on 2005-08. Estimated completion is 2010-02.

What conditions does trial NCT00121667 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00121667?

The interventions under investigation include: Pioglitazone (DRUG), Saxagliptin + Metformin (DRUG), Placebo + Metformin (DRUG).

Who is sponsoring clinical trial NCT00121667?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00121667 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00121667's enrollment target sits among peer trials

1,462 23rd of 348 higher than 326 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03936361 · 1,456 participants · Phase 3

    Statins In Intracerbral Hemorrhage

  • NCT06782347 · 1,454 participants · NA

    Activating SilverSneakers Benefits for Seniors With Osteoarthritis

  • NCT04566328 · 1,450 participants · Phase 3

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • NCT05229341 · 1,450 participants · NA

    Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00121667, the US trial registry maintained by the National Library of Medicine. NCT00121667 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.